EyePoint Pharmaceuticals, Inc.Find Ratings Reports
EYEPOINT PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the subsector, the net income growth did not. EYEPOINT PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 3.65 which clearly shows the ability to cover any short-term cash needs. EYPT managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 122.58% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY20||Q4 FY19|
|Net Sales ($mil)||7.13||8.63|
|Net Income ($mil)||-15.47||-10.41|
|Balance Sheet||Q4 FY20||Q4 FY19|
|Cash & Equiv. ($mil)||44.91||22.21|
|Total Assets ($mil)||91.72||72.97|
|Total Debt ($mil)||41.07||50.6|
|Profitability||Q4 FY20||Q4 FY19|
|Gross Profit Margin||-156.65||-96.55|
|Return on Assets||-49.49||-77.82|
|Return on Equity||-244.83||-681.79|
|Debt||Q4 FY20||Q4 FY19|
|Share Data||Q4 FY20||Q4 FY19|
|Shares outstanding (mil)||18.14||10.94|
|Div / share||0.0||0.0|
|Book value / share||1.02||0.76|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||354500.0||1138592.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 9.91 indicates a significant premium versus the S&P 500 average of 4.31 and a premium versus the subsector average of 8.58. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, EYEPOINT PHARMACEUTICALS INC proves to trade at a premium to investment alternatives.
|EYPT NM||Peers 28.45||EYPT NM||Peers 18.55|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
EYPT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
EYPT's P/CF is negative making the measure meaningless.
|EYPT NM||Peers 16.84||EYPT NA||Peers 0.38|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
EYPT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|EYPT 9.91||Peers 8.58||EYPT 38.04||Peers -13.01|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
EYPT is trading at a premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
EYPT is expected to have an earnings growth rate that significantly exceeds its peers.
|EYPT 5.34||Peers 10.93||EYPT 69.09||Peers 52.74|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
EYPT is trading at a significant discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
EYPT has a sales growth rate that significantly exceeds its peers.